Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure

Cardiology Clinics

Volumn 19, Issue 2, 2001, Pages 195-202

  Miller, Alan B ^b   Srivastava, Pankaj ^b  

^a UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ALDOSTERONE RECEPTOR; ANGIOTENSIN; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; CAPTOPRIL; LOSARTAN;

AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DIURESIS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; PATIENT MONITORING; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYMPTOMATOLOGY; UNITED STATES;

EID: 0034987826     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8651(05)70207-1     Document Type: Article

References (36)

1. Ectopic arrhythmia provoking action of aldosterone
2. Effects of adding spironolactone to an ACE inhibitor in chronic congestive heart failure secondary to coronary artery disease
3. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism
4. Capoten tablets: Captopril tablets
5. The Valsartan Heart Failure Trial (Val-HeFT)
6. Rationale and design of the valsartan heart failure trial: A large multi-national trial to assess the effects of valsartan, an angiotensin receptor blocker, on morbidity and mortality in chronic congestive heart failure
7. Losartan and heart failure: Hemodynamic effects and tolerability
8. Effects of losartan on blood pressure and left ventricular mass in essential hypertension
9. The physiology of congestive heart failure
10. Evidence for the role of an intracardiac renin-angiotensin system in normal and failing hearts
11. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: A substudy of the Studies of Left Ventricular Dysfunction (SOLVD)
12. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure
13. Tissue angiotensin converting enzyme in cardiac and vascular hypertrophy, repair, and remodeling
14. Rate and extent of left ventricular hypertrophy regression: A comparison of angiotensin II blockade with irbesartan and β blockade
15. Effects of losartan on exercise capacity, morbidity and mortality in patients with symptomatic heart failure
16. Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: Results of the ELITE ventricular function substudy
17. Effects of the angiotensin converting enzyme inhibitor enalapril on the long term progression of left ventricular dysfunction in patients with heart failure
18. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD): Pilot study
19. The angiotensin II type 2 (AT 2) receptor antagonizes the growth effects of the AT 1 receptor: Gain of function study using gene transfer
20. Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion
21. Renal and electrolyte complications of congestive heart failure with angiotensin converting enzyme inhibitors
22. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomized trial - The Losartan Heart Failure Survival Study ELITE II
23. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)
24. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
25. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES])
26. Myocardial production of aldosterone and corticosterone in the rat: Physiological regulation
27. Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
28. Modulation of the renin angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing induced heart failure: Effects on left ventricular performance and neurohormonal systems
29. Attenuation by spironolactone of the magnesiuric effect of acute frusemide administration in patients with liver cirrhosis and ascites
30. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure
31. Candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM): Rationale and design
32. Splanchnic extraction and clearance of aldosterone in patients with minimal and marked cardiac dysfunction
33. Production of aldosterone in isolated rat blood vessels
34. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension
35. Pathological hypertrophy and cardiac interstitium: Fibrosis and renin-angiotensin-aldosterone system
36. Interactions of mineralocorticoids and pressor agents in vascular smooth muscle